Skye Bioscience (SKYE, Financial) has announced the issuance of a stock option award as part of its strategic employee inducement efforts. On April 23, 2025, the company's Board of Directors authorized a non-qualified stock option to acquire 19,000 shares of Skye's common stock. This grant is extended to a newly hired non-executive employee, aligning with Skye's Amended and Restated 2024 Inducement Equity Incentive Plan.
The stock option award serves as an incentive for the employee's decision to join Skye Bioscience, in compliance with Nasdaq Listing Rule 5635(c)(4). This rule allows stock options to be granted as an employment inducement outside of shareholder-approved compensation plans, highlighting Skye's commitment to attracting and retaining talented professionals.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Skye Bioscience Inc (SKYE, Financial) is $20.00 with a high estimate of $20.00 and a low estimate of $20.00. The average target implies an upside of 998.90% from the current price of $1.82. More detailed estimate data can be found on the Skye Bioscience Inc (SKYE) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Skye Bioscience Inc's (SKYE, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
